-
Mashup Score: 3Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The Phase III TROPiCS-02 study found that the antibody-drug conjugate sacituzumab govitecan leads to #PFSbenefit over single-agent #chemotherapy in patients with pretreated HR+/HER2-, endocrine-resistant #metastatic breast cancer @UCSFCancer #bcsm #bcher: https://t.co/O98X4mMbLU https://t.co/mUYP7PtRH7
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The Phase III TROPiCS-02 study found that the antibody-drug conjugate sacituzumab govitecan leads to #PFSbenefit over single-agent #chemotherapy in patients with pretreated HR+/HER2-, endocrine-resistant #metastatic breast cancer @UCSFCancer #bcsm #bcher: https://t.co/XUzVc7Ym81 https://t.co/2RJVf2bx9t
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The Phase III TROPiCS-02 study found that the antibody-drug conjugate sacituzumab govitecan leads to #PFSbenefit over single-agent #chemotherapy in patients with pretreated HR+/HER2-, endocrine-resistant #metastatic breast cancer @UCSFCancer #bcsm #bcher: https://t.co/xtiWkCQAUP https://t.co/qcGmkmrB9V